Mammogen Bets Women Will Pay $500 For A Breast Cancer Blood Test
Direct Source Verification:
This story is aggregated from Forbes (forbes.com). Full reporting rights and copyright belong to the primary publisher.
Mammogen CEO Elizabeth Cormier-May plans to sell a $500 RNA blood test directly to women with dense breasts, backed by a pension-led Series A and a 2,600-woman trial.
For complete coverage, context, and related multimedia, visit the original reporting by Forbes via the source link below.
Original Source
https://www.forbes.com/sites/geristengel/2026/11/03/mammogen-bets-women-will-pay-500-for-a-breast-cancer-blood-test/
